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Intestinal Fibrosis Is Reduced by Early Elimination of
Inﬂammation in a Mouse Model of IBD: Impact of a
‘‘Top-Down’’ Approach to Intestinal Fibrosis in Mice
Laura A. Johnson, B.S.,* Amy Luke, B.S.,* Kay Sauder, B.S.,* David S. Moons, M.D., Ph.D.,†
Jeffrey C. Horowitz, M.D.,‡ and Peter D.R. Higgins, M.D., Ph.D, M.Sc.*
Background: The natural history of Crohn’s disease follows a path of progression from an inﬂammatory to a ﬁbrostenosing disease, with most
patients requiring surgical resection of ﬁbrotic strictures. Potent antiinﬂammatory therapies reduce inﬂammation but do not appear to alter the
natural history of intestinal ﬁbrosis. The aim of this study was to determine the relationship between intestinal inﬂammation and ﬁbrogenesis and
the impact of a very early ‘‘top-down’’ interventional approach on ﬁbrosis in vivo.
Methods: In this study we removed the inﬂammatory stimulus from the Salmonella typhimurium mouse model of intestinal ﬁbrosis by eradicat-
ing the S. typhimurium infection with levoﬂoxacin at sequential timepoints during the infection. We evaluated the effect of this elimination of
the inﬂammatory stimulus on the natural history of inﬂammation and ﬁbrosis as determined by gross pathology, histopathology, mRNA expres-
sion, and protein expression.
Results: Fibrogenesis is preceded by inﬂammation. Delayed eradication of the inﬂammatory stimulus by antibiotic treatment represses inﬂam-
mation without preventing ﬁbrosis. Early intervention signiﬁcantly ameliorates but does not completely prevent subsequent ﬁbrosis.
Conclusions: This study demonstrates that intestinal ﬁbrosis develops despite removal of an inﬂammatory stimulus and elimination of inﬂam-
mation. Early intervention ameliorates but does not abolish subsequent ﬁbrosis, suggesting that ﬁbrosis, once initiated, is self-propagating, sug-
gesting that a very early top-down interventional approach may have the most impact on ﬁbrostenosing disease.
(Inﬂamm Bowel Dis 2012;18:460–471)
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C rohn’s disease (CD) is characterized by repeatedcycles of intestinal inﬂammation (ﬂares) and healing.
Despite the increasing use of potent antiinﬂammatory
therapies which effectively treat inﬂammatory ﬂares, a
majority of CD patients ultimately develop ﬁbrostenotic
disease, necessitating surgical intervention at substantial
personal and economic costs.1–4 Indeed, some antiinﬂam-
matory therapies are associated with an increased risk of
stenosis, stricture, or obstruction.5 The persistence of intes-
tinal ﬁbrosis, and the failure of effective control of inﬂam-
mation to alter the natural history of CD, suggests that in-
testinal ﬁbrosis can pass a ‘‘point of no return,’’ after which
the ﬁbrotic process becomes autopropagative and fails to
respond to antiinﬂammatory interventions.6
In this study we used an experimental mouse model
of ﬁbrosing colitis to examine the impact of eliminating
the inﬂammatory stimulus on the development of ﬁbrosis.
In the Salmonella typhimurium model, inﬂammation is
driven by persistent S. typhimurium colonization of the
cecum. As described by Grassl et al.,7 chronic S. typhimurium
infection, which can persist up to 70 days, induces colitis and
severe tissue ﬁbrosis mainly in the cecum, characterized by
markedly reduced cecal size, transmural tissue ﬁbrosis, and a
Th1/Th17 cytokine proﬁle that recapitulates human CD.7,8 In
addition, the S. typhimurium model reproduces the bacterial
antigen stimulus of CD while readily allowing for the rapid
removal of the inﬂammatory stimulus with antibiotic treat-
ment. Thus, the model affords the opportunity to evaluate
how removal of inﬂammation at different timepoints impacts
the natural history of intestinal ﬁbrosis.
We describe the ﬁrst reported manipulation of the
S. typhimurium colitis model by intervention with levoﬂoxacin,
Received for publication May 25, 2011; Accepted June 2, 2011.
From the *Division of Gastroenterology and Hepatology, Department of
Internal Medicine, †Department of Pathology, ‡Division of Pulmonary and
Critical Care Medicine, Department of Internal Medicine, University of Michigan
Hospitals, Ann Arbor, Michigan.
Funded by National Institutes of Health (NIH) grant K08DK080172-01 (to
P.D.R.H.) and a grant from the University of Michigan Peptide Center.
Reprints: Peter D.R. Higgins, SPC 5682, 1150 West Medical Center Dr., Ann
Arbor, MI 48109 (e-mail: Phiggins@umich.edu).
Copyright VC 2011 Crohn’s & Colitis Foundation of America, Inc.
DOI 10.1002/ibd.21812
Published online 14 July 2011 in Wiley Online Library (wileyonlinelibrary.
com).
Inﬂamm Bowel Dis  Volume 18, Number 3, March 2012460
a ﬂuoroquinolone antibiotic with bactericidal activity
against intracellular bacteria. Very early antibiotic interven-
tion (a ‘‘top-down’’ approach) with levoﬂoxacin in S. typhi-
murium-infected mice repressed S. typhimurium-induced
inﬂammation and subsequent ﬁbrosis. However, late (day
8) eradication of S. typhimurium did not alter the develop-
ment of intestinal ﬁbrosis, suggesting that ﬁbrosis, once ini-
tiated, is self-propagative.
MATERIALS AND METHODS
Reagents
Levoﬂoxacin (levaquin in 5% dextrose, Hospira, Austin,
TX) was obtained from the University of Michigan Hospital
pharmacy.
Mice
Female 8–12-week-old CBA/J mice (Jackson Laborato-
ries, Bar Harbor, ME) received 20 mg streptomycin in 0.1 M
Hank’s buffered salt solution (HBSS) to eradicate the com-
mensal microbiota 24 hours prior to infection with 3  106
colony-forming units (cfu) S. typhimurium strain SL1344 in
100 k 0.1 M HEPES buffer (pH 8.0) by oral gavage. Control
mice received 100 k 0.1 M HEPES by oral gavage.
In the ﬁrst endpoint analysis experiment we examined
the effect of eradication of S. typhimurium at different time-
points after the infection (Fig. 1A). Mice were infected with
S. typhimurium as described above. To determine the natural
progression of inﬂammation and ﬁbrogenesis in this model,
S. typhimurium-infected mice (halting groups) were euthanized
at day 2, 4, 8, or 21 postinfection. Mice in the S. typhimurium-
infected levoﬂoxacin treatment groups (intervention groups)
received 0.5 mg/mL levoﬂoxacin ad libitum in drinking water
starting at day 2, 4, or 8 postinfection and continuing until
euthanasia at day 21 postinfection.
In the second time course comparison experiment,
which was designed to determine how early eradication of
S. typhimurium impacted inﬂammation and ﬁbrosis at early and
late timepoints (Fig. 1B), mice were infected with S. typhimu-
rium as described above. Half the infected animals then received
0.5 mg/mL levoﬂoxacin starting at day 3 postinfection through
day 21. Animals in the S. typhimurium/levoﬂoxacin group and
matched S. typhimurium-infected animals were euthanized at day
4, 12, or 21 postinfection. Uninfected control animals were
divided into two groups, of which half received 0.5 mg/mL levo-
ﬂoxacin in drinking water through day 21. Uninfected control
animals (treated with or without levoﬂoxacin) were euthanized at
day 21 of the study. All animal experiments were conducted
with the approval and oversight of the University of Michigan
UCUCA (University Committee on Use and Care of Animals).
Bacterial Strains
Salmonella typhimurium strain SL1344 (a gift from M.
O’Riordan, University of Michigan, Ann Arbor, MI), which is
naturally resistant to streptomycin, was grown in LB broth
containing 100 lg/mL streptomycin at 37C.
Gross Pathology and Tissue Collection
Cecum and distal colon were collected at sequential
timepoints post-S. typhimurium infection, photographed, meas-
ured, and weighed. Cecal area was determined from digital
photographs using ImageJ ROI (NIH, Bethesda, MD) to delin-
eate the cecum. To control for differences in focal distance,
cecal area was normalized against a 1-cm marker in the photo-
graphic image.
FIGURE 1. Treatment schematic of levoﬂoxacin endpoint analysis
and time course comparison experiments. (A) Treatment schematic
of the endpoint analysis experiment. Mice in the S. typhimurium
infection halting groups (upper panel) were treated with strepto-
mycin (strep, double arrows) 1 day prior to infection with S. typhi-
murium (S. typh, double arrows) and sacriﬁced at day 2, 4, 8, or 21
postinfection. In the levoﬂoxacin intervention groups (lower panel),
mice received streptomycin and S. typhimurium on the same
schedule. Levoﬂoxacin intervention (single arrows) began day 2, 4,
or 8 post-S. typhimurium infection and continued until sacriﬁce at
day 21 postinfection. (B) Treatment schematic of the time course
comparison experiments. Mice in the S. typhimurium infection
groups (upper panel) were treated with streptomycin (strep, dou-
ble arrows) 1 day prior to infection with S. typhimurium (S. typh,
double arrows) and sacriﬁced day 4, 12, or 21 postinfection. In the
levoﬂoxacin intervention time course (lower panel) mice received
streptomycin and S. typhimurium on the same schedule. Levoﬂoxa-
cin intervention (arrow) began day 3 post-S. typhimurium infection
and continued until sacriﬁce at day 4, 12, or 21 postinfection. In all
experiments ﬁve animals were used per experimental group.
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Tissues were snap-frozen in liquid nitrogen and stored
at 80C prior to molecular analysis. Cecal contents were col-
lected and serially diluted before plating onto LB-streptomycin
plates to determine bacterial titers.
Stool Cultures
A fresh stool was collected, suspended in 500 lL sterile
phosphate-buffered saline (PBS), streaked onto LB plates con-
taining 10 lg/mL streptomycin, and cultured overnight at 37C.
Histology
Formalin-ﬁxed and parafﬁn-embedded tissues were
stained with Masson’s trichrome by the University of Michigan
CCGC Research Histology and Immunoperoxidase Laboratory
(Ann Arbor, MI). Digital photomicrographs of tissue sections
were taken with an Olympus BX microscope (University of
Michigan Microscopy and Image Analysis Laboratory). Tissue
measurements were quantitated with ImageJ analysis software.
Histological Scoring
Histological scoring was performed in a blinded manner
by a pathologist (D.M.). Cecal inﬂammation was determined
using a Wirtz Scale 0 to 4 point scoring system as previously
described.9,10 Cecal ﬁbrosis was scored separately as follows:
(0) no ﬁbrosis; (1) mild ﬁbrosis (focal mucosal/submucosal
collagen deposition without architectural distortion); (2) mod-
erate ﬁbrosis (signiﬁcant mucosal/submucosal collagen deposi-
tion with modest distortion of mucosal/submucosal architec-
ture but without obscuring of the mucosal/submucosal border);
and (3) severe ﬁbrosis (extensive mucosal submucosal colla-
gen deposition with marked architectural distortion obscuring
the mucosal/submucosal border).
Immunoblotting
Immunoblotting was utilized for the detection of
a-smooth muscle actin (aSMA). Whole tissue was pulverized
under liquid nitrogen and lysed in ice-cold RIPA buffer with a
cocktail of proteinase inhibitors (Roche, Nutley, NJ). Protein
content was determined using a modiﬁed Bradford assay kit
(BioRad, Hercules, CA). Total protein was separated by so-
dium dodecyl sulfate polyacrylamide gel electrophoresis and
transferred to PVDF membranes (Amersham Biosciences, Pis-
cataway, NJ). Membranes were blocked in 5% milk solution
for 1 hour at room temperature or overnight at 4C. aSMA
was detected by incubating the membrane overnight at 4C
with mouse antihuman monoclonal antibody (Sigma, St.
Louis, MO) at 1:5000 dilution in 5% milk/TBST. As a loading
control, a mouse antibody for GAPDH (Chemicon, Temecula,
CA) was used after a stripping procedure. Secondary antibody
antimouse IgGþ horseradish peroxidase (HRP) (Amersham,
Piscataway, NJ) was incubated for 1 hour at room temperature
and the signal was detected by the Pierce detection system
(Pierce, Rockford, IL). Autoradiographs were scanned and
quantitated using Image J analysis software.
Real-time Quantitative Polymerase Chain
Reaction (PCR)
RNA was extracted from the cecum using the RNeasy kit
(Qiagen, Valencia, CA). Reverse transcription of 2 lg of total
RNA was performed with the Superscript First Strand RT kit
(Invitrogen, La Jolla, CA). Quantitative real-time PCR (qRT-
PCR) of IL-1b (Mm01336189_m1), TNFa (Mm00443258_m1),
IL-17 (Mm00439619_m1), IL-6 (Mm99999064_m1), IGF-1
(Mm00439560_m1), TGFb (Mm00441726_m1), IL-12p40
(Mm01288993_m1), CTGF (Mm01192933_g1), and GAPDH
(4352932E) was performed with the TaqMan assays-on-
demand primer/probe gene expression assays (ABI, Foster
City, CA). qRT-PCR was performed using a Stratagene
Mx3000P real-time PCR system (Stratagene, La Jolla, CA).
Cycling conditions were 95C 10 minutes, followed by 40
cycles of 95C 15 seconds and 62C 60 seconds. DDCt values
were calculated from GAPDHs expression.
Statistical Analysis
Comparisons between several groups of mice and asso-
ciated tissues or RNA expression were analyzed with analysis
of variance (ANOVA), while pairwise comparisons of two
groups were performed with Student’s t-test.
RESULTS
Inflammation Precedes Fibrosis in the
S. typhimurium Mouse Model of Intestinal Fibrosis
To determine the relationship between inﬂammation
and ﬁbrosis, mice were infected with S. typhimurium and sac-
riﬁced at day 2, 4, 8, or 21 postinfection (halting groups).
Disease activity was assessed by gross pathology, histopathol-
ogy, inﬂammatory and proﬁbrotic cytokine expression, and
aSMA protein expression. S. typhimurium heavily colonized
the mouse cecum at 1.7  107 cfu/mL by day 2 postinfection
and persisted through day 21 (3.4  107 cfu/mL, data not
shown). By day 2 postinfection, the gross cecal pathology
demonstrated a striking reduction in cecal size that persisted
and was virtually indistinguishable from the gross pathology
following a chronic 21-day infection (Fig. 2A). The gross
pathology was consistent with quantiﬁcation of cecal area,
which showed a signiﬁcant 2-fold reduction at day 2 that was
indistinguishable from the chronic day-21 group (Fig. 2B).
To determine the onset of intestinal inﬂammation,
cecal tissue sections were scored for inﬂammation on the
Wirtz scale (0 to 4).9,10 Early inﬂammatory changes were
seen at day 2 postinfection with a signiﬁcant increase in
histological inﬂammatory score compared to uninfected
animals (1.0 vs. 0.0, P < 0.001) (Fig. 2C). Inﬂammation
progressed during the course of infection through day 21.
The early gross phenotypic and inﬂammatory changes in
the cecum were associated with a rapid and dramatic
12–120-fold induction of proinﬂammatory Th1 cytokines
IL-1b and TNFa by day 2 postinfection which peaked by
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day 4 and persisted through day 21 (Fig. 2D,E). Similarly,
IL-12p40, a cytokine involved in both the Th1 and Th17
responses in the pathogenesis of CD,11 was markedly
induced by day 2 postinfection (Fig. 2F). S. typhimurium
infection also elicited an early Th17 response, characterized
by 17–19-fold induction of IL-17 and IL-6 cytokines by
day 2 postinfection which increased over the time course
of infection (Fig. 2G,H).
FIGURE 2. Inﬂammation precedes ﬁbrosis in the S. typhimurium mouse model of intestinal ﬁbrosis. (A) Representative gross appearance of
the cecum and distal colon of S. typhimurium-infected mice day 2 (d2), day 4 (d4), day 8 (d8), or day 21 (d21) postinfection compared to
uninfected (no Tx) against a 1-cm reference ruler. (B) Cecal area calculated from uninfected mice (no Tx) compared to S. typhimurium-
infected mice day 2, 4, 8, or 21 postinfection. (C) Blinded inﬂammatory scoring of cecal sections using the 0–4 point Wirtz scale. (D–H) qRT-
PCR gene expression of Th1 and inﬂammatory cytokines in the cecum of uninfected (no Tx) compared to S. typhimurium-infected mice day
2, 4, 8, or 21 postinfection. Gene expression was normalized to GAPDH expression. Statistical comparisons between uninfected controls (no
Tx) and the infected groups are denoted with asterisks. *P < 0.05, **P < 0.01, ***P < 0.001.
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The induction of ﬁbrosis followed the inﬂammatory
phase, with signiﬁcant increases in TGFb, IGF-1, and
CTGF expression observed at days 4–8 (Fig. 3A–C). In
contrast to the inﬂammatory cytokines, which peaked at
day 4, the ﬁbrogenic markers showed a progressive
increase through day 21 (Fig. 3A–C). Histopathological
analysis of trichrome-stained cecal tissue demonstrated
mild but signiﬁcant ﬁbrotic changes as early as day 2 post-
infection (1.2 vs. 0, P ¼ 0.04), which progressed to exten-
sive tissue ﬁbrosis with architectural distortion by day 21.
(Fig. 3D,E). An independent quantiﬁcation of trichrome
staining for collagen revealed a similar trend, with a mod-
est but signiﬁcant increase in collagen staining at day 2
postinfection with maximal collagen deposition by day 21
(data not shown). aSMA protein expression, a marker of
myoﬁbroblast activation, was not observed until day 8 and
continued to increase with a signiﬁcant 4-fold increase in
protein expression between day 8 and day 21 (Fig. 3F,G).
Intervention Reduces the S. typhimurium-induced
Inflammatory (Th1) Response
To determine whether the inﬂammatory response to
S. typhimurium infection persists without continued inﬂam-
matory stimulus (bacterial colonization), an endpoint analy-
sis experiment was performed. Mice were infected with
S. typhimurium and treated with oral doses of levoﬂoxacin
beginning at day 2, 4, or 8 postinfection and sacriﬁced at
day 21 (Fig. 1A). Within 24 hours of levoﬂoxacin adminis-
tration, 100% of the animals were negative for S. typhimu-
rium as determined by stool cultures (data not shown).
Gross pathology, histopathology, cytokine expression, and
protein expression were compared between animals in the
levoﬂoxacin intervention groups, uninfected animals, and
animals infected with S. typhimurium. Both early (day 2)
and later (days 4, 8) intervention reduced cecal contraction
and tissue weight at day 21 (Fig. 4A,B).
Histological analysis of inﬂammation in the cecal tis-
sue sections determined that early intervention reduced tis-
sue inﬂammation. Inﬂammation was signiﬁcantly repressed
in the day 2, 4, and 8 intervention groups at day 21 com-
pared to the infected group (0.6, 1.6, 1.6 vs. 3.8, P <
0.0001) (Fig. 4C). However, inﬂammation scores were still
signiﬁcantly higher at day 21 in the day 2, 4, and 8 levoﬂox-
acin intervention groups compared to uninfected animals
(0.6, 1.6, 1.6 vs. 0.0, P ¼ 0.04, P ¼ 0.004, P < 0.001).
Molecular analysis of the cecal tissue revealed a
more profound antiinﬂammatory effect of early interven-
tion. Early (day 2) intervention repressed the induction of
proinﬂammatory cytokines IL-1b, TNFa, and IL12p40 at
day 21 to levels indistinguishable from uninfected controls
(Fig. 4D–F). Although intervention at later timepoints
failed to completely abolish the induction of IL-1b, TNFa,
IL12p40, and IL-6 (Fig. 4H), the expression of these cyto-
kines was still markedly suppressed in comparison to the
untreated/S. typhimurium-infected animals. In contrast, both
early and late intervention repressed IL-17 (Fig. 4G).
Early Intervention Ameliorates But Does Not
Completely Prevent Fibrosis
Given that ﬁbrosis develops in response to inﬂamma-
tion, removal of the inﬂammatory stimulus would be expected
to limit ﬁbrosis. In mice treated with levoﬂoxacin at day 2 or
day 4 postinfection, expression of TGFb and CTGF cytokines
in the cecum at day 21 was indistinguishable from the expres-
sion in uninfected animals at day 21 postinfection. In contrast,
in the day 4 levoﬂoxacin group IGF-1 was still signiﬁcantly
elevated, reﬂecting a heterogeneous ﬁbrogenic response to
day 4 intervention (Fig. 5A–C). However, day 8 levoﬂoxacin
intervention did not alter the expression of the ﬁbrotic
markers at day 21 postinfection. TGFb, IGF-1, and CTGF
expression were signiﬁcantly induced compared to uninfected
animals and did not differ from S. typhimurium-infected ani-
mals at day 21 postinfection (Fig. 5A–C).
Similarly, histological scoring of ﬁbrosis revealed
that day 2 or 4 levoﬂoxacin intervention reduced tissue
ﬁbrosis at day 21 to levels indistinguishable from unin-
fected animals (0.4, 0.6 vs. 0.0, P ¼ 0.35, P ¼ 0.35,
respectively) (Fig. 5D). The later (day 8) levoﬂoxacin inter-
vention group had signiﬁcant tissue ﬁbrosis at day 21 that
was similar to the infected group at day 21 (1.8 vs. 2.8,
P ¼ 0.36) and signiﬁcantly greater than the ﬁbrosis in
uninfected controls (1.8 vs. 0.0, P < 0.001).
In contrast, aSMA protein expression at day 21 post-
infection was signiﬁcantly induced despite early interven-
tion with levoﬂoxacin (Fig. 5E,F). Although aSMA protein
expression in the early (day 2 and day 4) levoﬂoxacin
groups was 3–5-fold lower than the day 21 S. typhimurium-
infected mice, aSMA expression in all three intervention
groups was increased compared to uninfected controls at
day 21. During the course of infection, aSMA protein
expression was not induced until day 8 postinfection. How-
ever, the persistence of aSMA protein expression at day 21
in the infected/levoﬂoxacin-treated groups indicates that the
ﬁbrogenic process and myoﬁbroblast activation is initiated
early and persists despite removal of the inﬂammatory
stimulus and eradication of the inﬂammatory response.
Early Intervention Represses Gross Pathological
Changes and Inflammation
As demonstrated above, the ﬁbrogenic process is ini-
tiated between day 4 and day 8 with maximum ﬁbrosis at
day 21 postinfection. Therefore, in a second time course
comparison experiment we investigated the effect of early
removal of the inﬂammatory stimulus by treatment with lev-
oﬂoxacin at day 3 upon the development of ﬁbrosis over the
next 18 days (Fig. 1B). Following infection, S. typhimurium
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FIGURE 3. Development of ﬁbrosis in the S. typhimurium mouse model of ﬁbrosis. (A–C) qRT-PCR expression of ﬁbrotic genes in cecum from
uninfected mice (no Tx) compared to S. typhimurium-infected mice day 2, 4, 8, or 21 postinfection. Gene expression was normalized to GAPDH
expression. (D) Representative trichrome histological sections (100 magniﬁcation). (E) Blinded ﬁbrosis scoring of cecal sections was determined
from trichrome-stained cecal sections. (F) Representative western blot of aSMA protein expression in S. typhimurium mice days 2, 4, 8, or 21 post-
infection compared to uninfected controls. The samples shown were run on the same protein gel. The image has been cut to rearrange the
loading order for clarity. GAPDH expression was used as a loading control. (G) Quantitation of aSMA protein expression in cecum from uninfected
mice (no Tx) compared to S. typhimurium-infected mice day 2, 4, 8, or 21 postinfection. Western blots were digitally scanned and quantitated
using ImageJ. Relative expression was normalized to GAPDH protein expression. Statistical comparisons between uninfected controls (no Tx) and
the infected groups are denoted with asterisks. Brackets represent statistical comparisons between S. typhimurium-infected groups. *P < 0.05,
**P < 0.01, ***P < 0.001. [Color ﬁgure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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FIGURE 4. Intervention represses the inﬂammatory response. (A) Cecal area from uninfected mice (no Tx) compared to S. typhimurium-
infected mice day 2, 4, 8, or 21 postinfection, and S. typhimurium-infected mice treated with levoﬂoxacin day 2, 4, or 8 postinfection and
sacriﬁced day 21 postinfection. (B) Combined cecal þ colon weight. (C) Blinded inﬂammatory scoring of cecal sections using the 0–4 point
Wirtz scale. (D–H) qRT-PCR expression of IL-1b (D), TNFa (E), IL-12p40 (F), IL-17 (G), and IL-6 (H) in mice infected with S. typhimurium-
infected mice day 2, 4, 8, or 21 postinfection, and S. typhimurium-infected mice treated with levoﬂoxacin day 2, 4, or 8 postinfection and
sacriﬁced day 21 postinfection compared to uninfected mice (no Tx). Statistical comparisons between the infection groups or intervention
groups and the uninfected controls are denoted with asterisks. Statistically signiﬁcant comparisons between the S. typhimurium-infected
and levoﬂoxacin intervention groups at day 21 postinfection are denoted in brackets. *P < 0.05, **P < 0.01, ***P < 0.001.
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FIGURE 5. Early intervention ameliorates but does not completely prevent ﬁbrosis. (A–C) qRT-PCR expression of ﬁbrotic markers TGFb (A),
IGF-1 (B), and CTGF (C) in mice infected with S. typhimurium day 2, 4, 8, or 21 postinfection, and S. typhimurium-infected mice treated with
levoﬂoxacin day 2, 4, or 8 postinfection and sacriﬁced day 21 postinfection compared to uninfected mice (no Tx). (D) Blinded ﬁbrosis scor-
ing of cecal sections was determined from trichrome-stained cecal sections. (E) Representative western blot illustrating aSMA protein
expression in the cecum of uninfected mice (no Tx) compared to mice infected with S. typhimurium and treated with levoﬂoxacin 2, 4, or 8
postinfection and sacriﬁced day 21 postinfection and mice infected with S. typhimurium-infected mice day 2, 4, 8, or 21 postinfection.
GAPDH protein expression was used as a loading control. (F) Quantitation of aSMA protein expression in the cecum. Western blots were
digitally scanned and quantitated using ImageJ. Relative expression was normalized to GAPDH protein expression. Statistical comparisons
between the infection groups or intervention groups and the uninfected controls are denoted with asterisks. Statistically signiﬁcant com-
parisons between the S. typhimurium-infected and levoﬂoxacin intervention groups at day 21 postinfection are denoted in brackets. ns ¼
not statistically signiﬁcant, *P < 0.05, **P < 0.01, ***P < 0.001.
Inﬂamm Bowel Dis  Volume 18, Number 3, March 2012 Intestinal Fibrosis in a Mouse Model of IBD
467
was eradicated in half the animals by treatment with levo-
ﬂoxacin day 3 postinfection (during the inﬂammatory phase
of infection but before the ﬁbrogenic phase). Mice from
both the untreated and levoﬂoxacin intervention groups were
sacriﬁced at day 4, 12, or 21 postinfection to determine the
effect of eradication on inﬂammation and ﬁbrosis and com-
pared to uninfected animals that received either levoﬂoxacin
treatment or no intervention.
Twenty-four hours after initiating levoﬂoxacin ther-
apy, all animals in the intervention group had cleared the
S. typhimurium as determined by stool culture (data not
shown). In the day 4 postinfection group, this clearance was
associated with a concurrent change in gross pathology with
a small (17%) but signiﬁcant increase in cecal area com-
pared to matched day 4 S. typhimurium-infected animals.
(Fig. 6A) Similar improvement in cecal þ colon weight and
length were also observed (data not shown). By day 12 post-
infection the gross pathology of the levoﬂoxacin intervention
group was indistinguishable from uninfected controls.
Histological analysis of cecal tissue sections identi-
ﬁed signiﬁcant inﬂammation at both day 4 and day 12 in
the levoﬂoxacin-treated group compared to uninfected con-
trols (inﬂammation score 2.4 vs. 0.4 at day 4, P ¼ 0.035,
2.2 vs. 0.4 at day 12, P < 0.001) (Fig. 6B). Compared to
the matched S. typhimurium/untreated animals, inﬂamma-
tory scores were indistinguishable between the day 4
groups (2.4 vs. 2.8, P ¼ 0.25). Early Levoﬂoxacin inter-
vention did signiﬁcantly repress inﬂammation by day 12
and day 21 (2.2 vs. 3.8, P < 0.001 and 1.2 vs. 3.4, P <
0.001), although the inﬂammatory score in the levoﬂoxacin
intervention group at day 12 remained signiﬁcantly higher
than uninfected controls (1.2 vs. 0.4, P ¼ 0.035).
The histological inﬂammatory response was reﬂected
by a similar pattern of change in proinﬂammatory cytokine
gene expression. Cecal expression of proinﬂammatory cyto-
kines IL-1b, TNFa, and IL12p40 were signiﬁcantly induced
and did not differ in between the S. typhimurium-infected
and levoﬂoxacin-treated mice at day 4 postinfection com-
pared to uninfected controls (Fig. 6C–E). However, by day
12 postinfection IL-1b, TNFa, and IL12p40 expression was
signiﬁcantly reduced in levoﬂoxacin-treated compared to
day 12 infected and untreated mice.
Early intervention with levoﬂoxacin at day 3 exerted
a profound and immediate effect on the Th17 cytokine
response. At day 4 postinfection, IL-17 and IL-6 were
repressed 4-fold in the levoﬂoxacin intervention group
compared to the S. typhimurium group (Fig. 6F,G).
Early Intervention Represses Inflammation But
Does Not Prevent Fibrosis
Early intervention with levoﬂoxacin at day 3 postin-
fection repressed the induction of proﬁbrotic genes TGFb,
IGF-1, and CTGF. Although infection induced TGFb >3-
fold at day 4 postinfection, treatment with levoﬂoxacin at
day 3 repressed TGFb to levels indistinguishable from
uninfected controls (Fig. 7A). A similar trend occurred for
CTGF (Fig. 7C). Although IGF-1 was not induced until
later in the time course, levoﬂoxacin treatment signiﬁcantly
repressed IGF-1 induction (Fig. 7B).
Histologic scoring of cecal ﬁbrosis identiﬁed a signif-
icant reduction in ﬁbrosis in the levoﬂoxacin intervention
groups by day 12 and day 21. At day 12 the ﬁbrosis score
was signiﬁcantly lower in the intervention group compared
to the untreated group (2.0 vs. 3.0, P < 0.001) (Fig. 7D).
By day 21, ﬁbrosis had resolved in the levoﬂoxacin inter-
vention group to levels similar to uninfected controls (1.0
vs. 0.6, P ¼ 0.35).
aSMA protein expression was signiﬁcantly increased
at day 12 postinfection in both the levoﬂoxacin interven-
tion and S. typhimurium groups compared to uninfected
controls (Fig. 7E,F). While overall cecal aSMA protein
expression was lower in the levoﬂoxacin intervention
group, this was not statistically signiﬁcant at day 12 com-
pared to those without levoﬂoxacin treatment. By day 21
postinfection, aSMA protein expression was signiﬁcantly
repressed by 2.6-fold in the levoﬂoxacin intervention (P <
0.0001 vs. S. typhimurium-infected mice). Although aSMA
protein expression was attenuated at day 21 in the levoﬂox-
acin intervention group compared to S. typhimurium-
infected mice, aSMA protein was still signiﬁcantly higher
compared to uninfected controls, suggesting early interven-
tion attenuated but did not completely resolve myoﬁbro-
blast activation and ﬁbrogenesis.
DISCUSSION
CD, despite available potent antiinﬂammatory thera-
pies, largely progresses to a complicated ﬁbrostenosing phe-
notype. Current therapies induce and maintain remission of
inﬂammation but have a poor record in preventing ﬁbroste-
notic complications, with a majority of CD patients inexor-
ably progressing towards ﬁbrostenotic disease and subse-
quent surgical intervention.1–3,12,13 In a small recent study,
20% of CD patients with ﬁbrostenotic disease treated with
biologics required surgical intervention within 2 to 5 years.14
Current therapies that target inﬂammation do not alter the
natural history of CD, suggesting that intestinal ﬁbrosis,
once initiated, becomes irreversible.15
To better understand why antiinﬂammatory therapy fails
to alter the natural history of intestinal ﬁbrosis, we examined
the temporal relationship between inﬂammation and ﬁbrosis
and the consequences of removal of inﬂammation from the S.
typhimurium murine model of ﬁbrosis. Although other murine
colitis models (PG-PS, TNBS, DSS) are commonly used to
study IBD, these have limitations for elucidating the pathobi-
ology of ﬁbrosis due to inherent murine resistance to ﬁbrotic
disease, incomplete disease penetrance, and high mortality.8
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In addition, none are particularly amenable to experimental
manipulation of inﬂammation. Our study, the ﬁrst systematic
manipulation inﬂammation in a rodent colitis model, demon-
strates that eradication of the inﬂammatory stimulus is not suf-
ﬁcient to prevent progression of ﬁbrosis. As we demonstrated
in the infection time course comparison experiments, inﬂam-
matory changes occur early (day 2) and precede ﬁbrogenesis
(day 4 to day 8). Treatment of S. typhimurium-infected mice
with levoﬂoxacin at days 2, 4, and 8 postinfection reversed
inﬂammatory changes in gross pathology, histopathology, and
repressed the Th1/Th17 inﬂammatory cytokine gene expres-
sion at day 21 postinfection. However, levoﬂoxacin interven-
tion at day 4 or day 8 failed to prevent ﬁbrogenesis at day 21
postinfection, as evidenced by increased proﬁbrotic gene
FIGURE 6. Early intervention represses inﬂammation. (A) Levoﬂoxacin intervention reverses cecal contraction in response to S. typhimurium
infection. Cecal area of mice infected with S. typhimurium (solid diamonds) compared to S. typhimurium-infected animals treated with levo-
ﬂoxacin day 3 postinfection (open circles) at day 4, 12, or 21 postinfection. (B) Blinded inﬂammatory scoring of cecal sections using the 0–4
point Wirtz scale. (C–G) qRT-PCR expression of IL-1b, TNFa IL-12p40, IL-17, and IL-6 in the cecum day 4, 12, or 21 postinfection. Statistical
comparisons between the infection and intervention groups are denoted with asterisks. *P < 0.05, **P < 0.01, ***P < 0.001.
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expression, increased tissue ﬁbrosis, and increased aSMA pro-
tein expression. Strikingly, ﬁbrosis not only persisted, but
actually progressed even after eradication of the inﬂammatory
stimulus, suggesting that established ﬁbrosis is not readily re-
versible, even with eradication of the inciting inﬂammatory
stimulus. Further, this suggests that established intestinal
ﬁbrogenesis is, to some extent, a self-sustaining process.
Current CD treatment paradigms follow a ‘‘step-up’’
approach in which increasing disease severity (ﬂares) or
treatment failure drives therapeutic escalation.16 However,
recent clinical studies suggest an early, aggressive, or ‘‘top-
down’’ approach may improve patient outcomes.17,18 To
determine whether a top-down approach alters the natural his-
tory of intestinal ﬁbrosis, we treated S. typhimurium-infected
FIGURE 7. Early intervention represses inﬂammation but does not prevent ﬁbrosis. (A–C) qRT-PCR expression of ﬁbrotic markers TGFb (A),
IGF-1 (B), and CTGF (C) in mice infected with S. typhimurium (solid diamonds) compared to S. typhimurium-infected mice treated with levo-
ﬂoxacin day 3 postinfection (open circles) day 4, 12, or 21 postinfection. (D) Blinded ﬁbrosis scoring of cecal sections was determined from
trichrome stained cecal sections. (E) Representative western blot of cecal aSMA protein expression in mice infected with S. typhimurium com-
pared to mice infected with S. typhimurium and treated with levoﬂoxacin, uninfected mice (no Tx), and levoﬂoxacin-treated uninfected mice
(Levo). GAPDH was used as a control for protein loading. (F) aSMA protein expression in the cecum in response to S. typhimurium infection or
S. typhimurium infection and levoﬂoxacin intervention. Relative aSMA expression was normalized to GAPDH expression. Statistically signiﬁcant
comparisons between the infection and intervention groups are denoted with asterisks. *P < 0.05, **P < 0.01, ***P < 0.001.
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mice with levoﬂoxacin at day 3 postinfection and com-
pared the impact on progression of ﬁbrosis with infected
mice at days 4, 12, and 21 postinfection. Consistent with
a potential beneﬁt to the top-down approach, early inter-
vention improved tissue pathology as determined by gross
pathology and histopathology, and repressed the induction
of inﬂammatory and proﬁbrogenic genes. In addition,
early intervention suppressed, yet did not completely
abrogate, induction of aSMA protein expression, suggest-
ing partial myoﬁbroblast activation. In contrast, late eradi-
cation of the inﬂammatory stimulus did not prevent
ﬁbrotic progression.
In summary, our study demonstrates that by manipu-
lating a rodent model of ﬁbrosing colitis we can examine
biologically and clinically important questions concerning
the interaction between inﬂammation and ﬁbrosis. Late
removal of the inﬂammatory stimulus does not prevent sub-
sequent tissue ﬁbrosis, suggesting a ‘‘point of no return’’ at
which ﬁbrogenesis becomes autopropagative. This ﬁnding
is similar to studies demonstrating that liver ﬁbrosis is
reversible if the activating stimulus is suppressed at an early
timepoint.19 While no human study has yet addressed the
connection between very early use of biologics (antiinﬂam-
matory therapy within a week of diagnosis) and the develop-
ment of ﬁbrostenotic disease, we demonstrate here that very
early therapeutic intervention can ameliorate the late end-
point of ﬁbrosis. These ﬁndings support the potential bene-
ﬁts of a very early top-down treatment approach,17 and sug-
gest that the beneﬁts may wane as the time between the
start of symptoms and therapeutic intervention increases.
CD is chronic and progressive, with a natural history
ﬁlled with complications. Currently, we cannot reliably
stratify patients by their risk of ﬁbrostenotic disease.20
Given that current therapies target inﬂammation, no effec-
tive antiﬁbrotics exist, and that once initiated, and that ﬁ-
brosis can autopropagate even in the absence of inﬂamma-
tion, very early intervention or a top-down approach may
have the greatest impact on the natural history of CD.
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